George Elston - Jan 3, 2025 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
Chief Financial Officer
Signature
/s/ Ron Honig, Attorney-in-Fact
Stock symbol
EYPT
Transactions as of
Jan 3, 2025
Transactions value $
-$85,239
Form type
4
Date filed
1/7/2025, 04:04 PM
Previous filing
May 28, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +15K +31.02% $0.00 63.4K Jan 5, 2025 Direct F1
transaction EYPT Common Stock Tax liability -$43.5K -5.27K -8.31% $8.26 58.1K Jan 5, 2025 Direct F2
transaction EYPT Common Stock Options Exercise $0 +15.3K +26.31% $0.00 73.4K Jan 6, 2025 Direct
transaction EYPT Common Stock Tax liability -$41.7K -4.81K -6.55% $8.68 68.6K Jan 6, 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Award $0 +59K +393.33% $0.00 74K Jan 3, 2025 Common Stock 59K $0.00 Direct F3
transaction EYPT Stock Option (Right to Buy) Award $0 +117K $0.00 117K Jan 3, 2025 Common Stock 117K $8.26 Direct F4
transaction EYPT Restricted Stock Units Options Exercise $0 -15K -33.33% $0.00 30K Jan 5, 2025 Common Stock 15K $0.00 Direct F5
transaction EYPT Restricted Stock Units Options Exercise $0 -15.3K -50.95% $0.00 14.7K Jan 6, 2025 Common Stock 15.3K $0.00 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 876 shares acquired on July 31, 2024 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.
F2 No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units.
F3 The restricted stock units will vest in three ratable annual installments beginning January 3, 2026.
F4 The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years.
F5 The restricted stock units vests in three ratable annual installments beginning January 5, 2025.
F6 The restricted stock units vests in three ratable annual installments beginning January 6, 2024.